Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | CMWP & EBMT report: allogeneic HCT outcomes in myeloma patients on renal replacement

Meral Beksac • 31 Aug 2020
EBMT 2020
Multiple Myeloma

Meral Beksac, MD, Ankara University, Ankara, Turkey, discusses a Chronic Malignancies Working Party (CMWP) and European Society for Blood and Marrow Transplantation (EBMT) report that investigated allogeneic hematopoietic cell transplantation (HCT) outcomes in myeloma patients on renal replacement. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meral Beksac

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma 1:38
Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma
Meral Beksac • 17 Sep 2025
Improving CAR T-cell responsiveness and overcoming resistance in multiple myeloma 3:02
Improving CAR T-cell responsiveness and overcoming resistance in multiple myeloma
Meral Beksac • 17 Sep 2025
Strategies to enhance the efficacy of CAR T-cell therapy in multiple myeloma 1:56
Strategies to enhance the efficacy of CAR T-cell therapy in multiple myeloma
Meral Beksac • 17 Sep 2025

Related Videos

Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma 3:53
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa • 16 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals